Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Raw Materials: 2023-2024

Historic Raw Materials for Tg Therapeutics (TGTX) over the last 2 years, with Dec 2024 value amounting to $28.2 million.

  • Tg Therapeutics' Raw Materials rose 134.08% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 134.08%. This contributed to the annual value of $28.2 million for FY2024, which is 327.70% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Raw Materials is $28.2 million, which was up 327.70% from $6.6 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Raw Materials ranged from a high of $28.2 million in FY2024 and a low of $6.6 million during FY2023.
  • Over the past 2 years, Tg Therapeutics' median Raw Materials value was $17.4 million (recorded in 2023), while the average stood at $17.4 million.
  • Data for Tg Therapeutics' Raw Materials shows a peak YoY spiked of 327.70% (in 2024) over the last 5 years.
  • Tg Therapeutics' Raw Materials (Yearly) stood at $6.6 million in 2023, then soared by 327.70% to $28.2 million in 2024.